Casado JL, et al. - In this study, researchers focussed on the evolution of renal function in HIV-infected patients who switched to a dual regimen including dolutegravir (DTG), rilpivirine (RPV) or darunavir/cobicistat (COBI), separately or in combination. In this prospective cohort study, they included 288 patients on different dual regimens (DTG + RPV, 92; DTG + darunavir/COBI, 23; DTG, 26; COBI, 19; control group, 128). Patients using different antiretroviral drugs inhibiting the tubular transport of creatinine, separately or in combination, showed similar serum creatinine-based estimated glomerular filtration rate (eGFR-scr) decreases, with no alterations in proteinuria or cystatin C-based eGFR. When the drugs were used in combination, no additional changes were observed, and there was lower impact among cases of previous chronic kidney disease. These findings suggest the existence of compensatory mechanisms for creatinine secretion.